Prof. Hao Wang’s group was founded in 2011. It belongs to CAS Key Lab for Biomedical Effects of Nanomaterials and Nanosafety. It consists of two full professors, two associate professors, postdoctors and students.  

　　Prof. Wang received his Bachelor's degree (2000) and obtained his PhD degree in chemistry from Nankai University of China in 2005. He worked as an Alexander von Humboldt (AvH) Fellow in Universät Würzburg of Germany (2005-2007). Later, He worked as a postdoctoral research fellow at the Department of Molecular and Medical Pharmacology, of University of California, Los Angeles (2007-2011). From 2011 onwards, he is working as a principal investigator at Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety in National Center for Nanoscience and Technology of China. He has published over 90 peer-reviewed papers in leading journals, including Angew. Chem. Int. Ed., JACS, Adv. Mater., ACS Nano, Biomaterials ,etc. He has been authorized 6 granted patents, of which two are the United States Patent. He was invited to write the review article in Adv. Mater. and Nanoscale. Moreover, he was invited by RSC and Springer publisher to contribute two chapters, respectively. He is principle investigator of several domestic and international projects, such as 100 Talents Program of The Chinese Academy of Sciences, National Key Basic Research Program of China (973 Program), projects from National Natural Science Foundation of China, Beijing Natural Science Foundation and Key Project of Chinese Academy of Sciences in Cooperation with Foreign Enterprises 

　　Research interests:  

　　His current research interests are to i) develop "in vivo self-assembly" technology in physiological/pathological conditions; ii) study their bio-effect and further regulate biological behavior; iii) explore self-assembled biomaterials for bioimaging, drug delivery, immunotherapy etc. We envision that the combination of modular molecular assembly strategy and modern in vivo diagnostics/therapeutics represents an important paradigm shift for biomaterial development, drug discovery and clinical patient management applications.